Comparative Pharmacology
Head-to-head clinical analysis: CODEPREX versus DIMETANE DX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODEPREX versus DIMETANE DX.
CODEPREX vs DIMETANE-DX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.
Dimetane-DX contains brompheniramine (first-generation antihistamine) and dextromethorphan (NMDA receptor antagonist and sigma-1 agonist). Brompheniramine antagonizes histamine at H1 receptors, reducing allergic symptoms; dextromethorphan suppresses cough by acting on the cough center in the medulla oblongata via NMDA receptor antagonism and sigma-1 receptor activation.
Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
Adults and children ≥12 years: One tablet (brompheniramine 4 mg, dextromethorphan 10 mg, phenylephrine 10 mg) orally every 4 hours as needed, not to exceed 4 doses in 24 hours.
None Documented
None Documented
4-6 hours (prolonged to 10-12 hours in hepatic impairment)
Brompheniramine: 25-30 hours; guaifenesin: 1 hour; dextromethorphan: 2-4 hours (CYP2D6 extensive metabolizers) or 20-40 hours (poor metabolizers).
Renal: 60% as unchanged drug; Hepatic metabolism: 30% (inactive metabolites); Fecal: 10%
Renal: 50-70% (brompheniramine) as metabolites and unchanged drug; guaifenesin metabolites primarily renal; dextromethorphan and metabolites renal. Biliary/fecal: minor.
Category C
Category C
Antitussive Combination
Antitussive Combination